Weill Cornell Mantle Cell Lymphoma (MCL) Research

What is Mantle Cell Lymphoma (MCL)?

Weill Cornell Mantle Cell Lymphoma (MCL) Program

What is Minimal Residual Disease (MRD)?

Hodgkin Lymphoma | Katie's Story

Circulating Tumor DNA and the Future of Lymphoma Care

The Stages of Lymphoma

Dr. John Leonard at ASCO 2018: Vitamin D Supplementation

REGN1979 for Patients with Previously Treated CD20 Positive B-cell Malignancies

REDLAMP 15: Outcomes for Patients with Mantle Cell Lymphoma after Ibrutinib

REDLAMP 14: Does Routine Imaging After DLBCL Remission Improve Post-Treatment Survival?

REDLAMP 13: How Are Outcomes Improving for Patients with Transformed Follicular Lymphoma?

Sarah Rutherford, M.D.

Jia Ruan, M.D., Ph.D.

Richard Furman, M.D.

Peter Martin, M.D.

John Leonard, M.D.

Lymphoma Program | Weill Cornell Medicine

Copanlisib for People with MCL Previously Treated with Ibrutinib

REDLAMP 12: Lenalidomide & Rituximab Combo Promising as Initial Treatment for Mantle Cell Lymphoma

REDLAMP 11: Does a Family History of Lymphoma Increase My Risk?

Selinexor and RICE Chemotherapy in relapsed/refractory DLBCL

REDLAMP 10: Can Physical Activity Lower the Risk of Non-Hodgkin Lymphoma?

REDLAMP 9: Prognostic Factors for Clinical Outcomes in Patients with Plasmablastic Lymphoma

REDLAMP 8: Does a Geriatric Assessment Hold Prognostic Value for Patients with Aggressive NHL?

REDLAMP 7: Parenthood in Adult Female Survivors Treated for Hodgkin Lymphoma as a Child & Teenager

Nivolumab for Relapsed Hodgkin Lymphoma Clinical Trial | Weill Cornell Medical College | New York

REDLAMP 6: Entecavir vs. Lamivudine in Preventing Hepatitis B Reactivation in Untreated DLBCL

REDLAMP 5: Rituximab vs. Watch & Wait Approach in Patients with Advanced Follicular Lymphoma

REDLAMP 4: Circulating Tumor DNA & CT Monitoring for Untreated DLBCL - A Correlative Biomarker Study